Abstract: The invention is in the field of molecular immunology, more in particular in the field of medical treatment of animals such as humans suffering from unwanted immune reactions. The invention relates to methods for the treatment of unwanted immune reactions and provides means and methods for suppressing an immune response. The present invention relates in particular to regulatory T cells and methods of long-term, culture-expanding, activating and using same in immunotherapy and for the suppression of autoimmune responses, allergies and inflammatory diseases. The invention provides a sia alpha 2,3-conjugated antigen for use in the suppression of an immune response in a patient in need of such a treatment.
Type:
Application
Filed:
December 15, 2011
Publication date:
March 13, 2014
Applicant:
VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJS
Abstract: C-type lectins are involved in the binding of many different types of carbohydrates. Considering their diversity in kind and expression of different types of cells, the influence of such binding is very diverse and dependent among others on the type of cell, the environment of the cell and the type of carbohydrate bound. In the present invention new carbohydrate specificities of C-type lectins are disclosed. Interference with this binding property has uses in the prevention of pathogen binding and also in influencing signaling pathways in the C-type lectin containing cell, particularly in Toll like receptor expressing cells such as dendritic cells. Also provided is the use of the carbohydrate specificity to enhance antigen presentation by antigen presenting cells and to manipulate migration of C-type lectin containing cells and the interaction of C-type lectin expressing cells with cellular ligands on neighboring cells.
Type:
Grant
Filed:
November 7, 2003
Date of Patent:
November 13, 2012
Assignee:
Vereniging voor Christelijk Wetenschappelijk Onderwijs
Inventors:
Teunis Bernard Herman Geijtenbeek, Yvette van Kooyk
Abstract: Methods and compositions for the treatment of multiple sclerosis comprising riluzole (6-(trifluoromethoxy)-benzothiazolamine) are disclosed herein.
Type:
Grant
Filed:
March 25, 2005
Date of Patent:
March 11, 2008
Assignee:
Vereniging Voor Christelijk Wetenschappelijk Onderwijs